As of January 22, 2025, Allogene Therapeutics (ALLO) has a market cap of $0.40 billion USD. According to our data, Allogene Therapeutics is ranked No.6385 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.40 B |
-9.86%
|
Dec 31, 2024 | $0.45 B |
-33.64%
|
Dec 29, 2023 | $0.67 B |
-48.97%
|
Dec 30, 2022 | $1.32 B |
-57.84%
|
Dec 31, 2021 | $3.13 B |
-40.89%
|
Dec 31, 2020 | $5.29 B |
-2.85%
|
Dec 31, 2019 | $5.45 B |
-3.53%
|
Dec 31, 2018 | $5.65 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
bluebird bio
BLUE
|
$77.49 M |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Atara Biotherapeutics
ATRA
|
$39.63 M |
0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.14 B |
0.000 M
|
UK
|
Precision BioSciences
DTIL
|
$38.43 M |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Market Cap | = | ALLO Stock Price | * | ALLO Shares Outstanding |
= | $1.92 | * | 0.21 B | |
= | $0.40 B |